T790M-话题@MedSci

#T790M#

29篇内容 | 1460人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1795254, encodeId=d8f71e95254d4, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Ann Oncol：奥希替尼治疗T790M阳性NSCLC脑转移：两项II期研究合并分析, objectType=article, longId=129881, objectId=12e61298813e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12e61298813e, replyNumber=0, likeNumber=64, createdTime=2018-10-31, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12e61298813e, moduleTitle=Ann Oncol：奥希替尼治疗T790M阳性NSCLC脑转移：两项II期研究合并分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12e61298813e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795253, encodeId=69701e952530f, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Lung cancer:液体活检T790M突变低丰度建议组织活检除外SCLC转化, objectType=article, longId=121421, objectId=96241214210b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96241214210b, replyNumber=0, likeNumber=111, createdTime=2018-08-29, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96241214210b, moduleTitle=Lung cancer:液体活检T790M突变低丰度建议组织活检除外SCLC转化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96241214210b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795252, encodeId=d2121e9525255, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？, objectType=article, longId=114385, objectId=e7721143856c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7721143856c, replyNumber=0, likeNumber=79, createdTime=2018-03-11, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7721143856c, moduleTitle=【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7721143856c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795250, encodeId=82ac1e9525013, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=T790M突变检测，实现EGFR TKI耐药患者的精准治疗, objectType=article, longId=108175, objectId=29721081e5ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29721081e5ad, replyNumber=0, likeNumber=70, createdTime=2017-11-12, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29721081e5ad, moduleTitle=T790M突变检测，实现EGFR TKI耐药患者的精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29721081e5ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795251, encodeId=f4251e95251a6, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=2017 澳大利亚建议：晚期非小细胞肺癌EGFR T790M检测, objectType=article, longId=112235, objectId=99941122356a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99941122356a, replyNumber=0, likeNumber=68, createdTime=2018-03-27, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99941122356a, moduleTitle=2017 澳大利亚建议：晚期非小细胞肺癌EGFR T790M检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99941122356a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795249, encodeId=0f671e952490b, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Lancet Respir Med：埃罗替尼与贝伐单抗联合用药使非小细胞肺癌T790M突变患者获益, objectType=article, longId=98017, objectId=688e9801ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=688e9801ee7, replyNumber=0, likeNumber=103, createdTime=2018-02-25, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=688e9801ee7, moduleTitle=Lancet Respir Med：埃罗替尼与贝伐单抗联合用药使非小细胞肺癌T790M突变患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=688e9801ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795248, encodeId=0c6c1e9524855, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=NEJM：EGFR T790M阳性的肺癌患者该如何选择治疗方案呢？, objectType=article, longId=83693, objectId=d1e7836934b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1e7836934b, replyNumber=0, likeNumber=63, createdTime=2017-01-04, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1e7836934b, moduleTitle=NEJM：EGFR T790M阳性的肺癌患者该如何选择治疗方案呢？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1e7836934b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795247, encodeId=5c861e95247fe, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=2016NICE技术评估指南：osimertinib用于治疗局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌（TA416）发布, objectType=article, longId=81116, objectId=25a48111657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25a48111657, replyNumber=0, likeNumber=59, createdTime=2017-10-01, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25a48111657, moduleTitle=2016NICE技术评估指南：osimertinib用于治疗局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌（TA416）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25a48111657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795246, encodeId=5e0f1e9524652, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=ELCC 2016：Tagrisso一线治疗EGFR T790M突变NSCLC患者，PFS长达19.3个月, objectType=article, longId=66570, objectId=3bc2665e07d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bc2665e07d, replyNumber=0, likeNumber=69, createdTime=2016-08-23, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bc2665e07d, moduleTitle=ELCC 2016：Tagrisso一线治疗EGFR T790M突变NSCLC患者，PFS长达19.3个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bc2665e07d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795245, encodeId=e1971e95245cf, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=ASCO 2014：T790M的异质性状态影响EGFR-TKI耐药NSCLC的化疗结果, objectType=article, longId=35691, objectId=a7ba35691f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7ba35691f6, replyNumber=0, likeNumber=95, createdTime=2015-03-04, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7ba35691f6, moduleTitle=ASCO 2014：T790M的异质性状态影响EGFR-TKI耐药NSCLC的化疗结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7ba35691f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795244, encodeId=f7481e95244b0, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=ACIEE：针对非小细胞肺癌EGFRT790M突变体的靶向化合物被设计, objectType=article, longId=21032, objectId=41df210325e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41df210325e, replyNumber=0, likeNumber=67, createdTime=2014-04-30, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41df210325e, moduleTitle=ACIEE：针对非小细胞肺癌EGFRT790M突变体的靶向化合物被设计, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41df210325e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

T790M

2020-05-29

zhlpower (审核中...)

前往app查看评论内容

#T790M#

Ann Oncol：奥希替尼治疗T790M阳性NSCLC脑转移：两项II期研究合并分析

2018-10-31

zhlpower (审核中...)

前往app查看评论内容

#T790M#

Lung cancer:液体活检T790M突变低丰度建议组织活检除外SCLC转化

2018-08-29

zhlpower (审核中...)

前往app查看评论内容

#T790M#

【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？

2018-03-11

zhlpower (审核中...)

前往app查看评论内容

#T790M#

T790M突变检测，实现EGFR TKI耐药患者的精准治疗

2017-11-12

zhlpower (审核中...)

前往app查看评论内容

#T790M#

2017 澳大利亚建议：晚期非小细胞肺癌EGFR T790M检测

2018-03-27

zhlpower (审核中...)

前往app查看评论内容

#T790M#

Lancet Respir Med：埃罗替尼与贝伐单抗联合用药使非小细胞肺癌T790M突变患者获益

2018-02-25

zhlpower (审核中...)

前往app查看评论内容

#T790M#

NEJM：EGFR T790M阳性的肺癌患者该如何选择治疗方案呢？

2017-01-04

zhlpower (审核中...)

前往app查看评论内容

#T790M#

2016NICE技术评估指南：osimertinib用于治疗局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌（TA416）发布

2017-10-01

zhlpower (审核中...)

前往app查看评论内容

#T790M#

ELCC 2016：Tagrisso一线治疗EGFR T790M突变NSCLC患者，PFS长达19.3个月

2016-08-23

zhlpower (审核中...)

前往app查看评论内容

#T790M#

ASCO 2014：T790M的异质性状态影响EGFR-TKI耐药NSCLC的化疗结果

2015-03-04

zhlpower (审核中...)

前往app查看评论内容

#T790M#

ACIEE：针对非小细胞肺癌EGFRT790M突变体的靶向化合物被设计

2014-04-30

科室
- - 订阅+
  - 更多科室
工具
服务